A systematic review of sodium-glucose cotransporter 2 inhibitors and renal profiles among Japanese patients with type 2 diabetes mellitus

Table 2 Summary of subgroup analyses

	Outcome	Trial, n	Study name(s) merged	SGLT2i, n	Placebo, n	MD [95%CI]	I², %	p
Only patients with T2DM and renal impairment	SCr, mg/dL	2	Haneda 2016 [15] Kashiwagi 2015 A [16]	213	96	0.03 [0.01, 0.05]	0	0.003
	eGFR, mL/min/1.73 m²	3	Haneda 2016 [15] Kashiwagi 2015 A [13] Wada 2022 [10]	340	220	-1.00 [-3.04, 1.03]	66	0.33
Only patients with T2DM and normal renal function	SCr, mg/dL	8	Inagaki 2014 [20] Kaku 2014 [21] Kashiwagi 2015B [17] Kashiwagi 2015 C [18] Kashiwagi 2015D [19] Seino 2014 A [22] Seino 2014B [23] Seino 2014 C [24]	1138	508	0.01 [0.00, 0.02]	0	0.008
	eGFR, mL/min/1.73 m²	6	Kaku 2014 [21] Kaku 2021 [13] Kashiwagi 2015B [17] Kashiwagi 2015 C [18] Kashiwagi 2015D [19] Seino 2018 [14]	715	374	-1.43 [-2.48, -0.37]	1	0.008
Only patients with T2DM treated with a SGLT2i as monotherapy	SCr, mg/dL	6	Inagaki 2014 [20] Kaku 2014 [21] Kashiwagi 2015D [19] Seino 2014 A [22] Seino 2014B [23] Seino 2014 C [24]	876	379	0.01 [0.00, 0.02]	0	0.02
	eGFR, mL/min/1.73 m²	2	Kaku 2014 [21] Kashiwagi 2015D [19]	226	115	-2.97 [-5.12, -0.81]	0	0.007

SGLT2i sodium-glucose cotransporter 2 inhibitors, T2DM type 2 diabetes mellitus, NA not applicable, I² heterogeneity, SCr serum creatinine, eGFR estimated glomerular filtration rate, MD weighted mean difference.

ISSN: 2055-0294